Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Vaccine
HER2/neu vaccine prevents recurrence in high-risk breast cancer patients
December 29th, 2005
An HER2/neu vaccine prevents recurrence in high-risk breast cancer patients. "E75 is an immunogenic peptide from the HER2/neu protein that is highly expressed in breast cancer. We are conducting a clinical trial of an E75 + granulocyte-macrophage colony-stimulating factor vaccine to assess safety, immunologic response, and the prevention of clinical recurrences in patients with disease-free, node-positive breast cancer (NPBC)." "Fifty-three patients with NPBC were enrolled and HLA typed. HLA-A2+ patients (n=24) were vaccinated, and HLA-A2- patients (n=29) are observed prospectively as clinical controls," scientists in the United States report. ...
Source: Women's Health Weekly (2005-12-29)
|
